Acorda CTO Batycky Leaves to Run Biotech Startup

Xconomy New York — 

[Corrected 8/14/18, 9:45 am. See below.] Acorda Therapeutics (NASDAQ: ACOR) chief technology officer Rick Batycky is leaving the company to become the CEO of a private, venture-backed biotech. Batycky’s duties are being taken up by Acorda chief of business operations David Lawrence and chief medical officer Burkhard Blank, the company said. [Corrected title in headline. We regret the error.]